" class="no-js "lang="en-US"> Paul Davis - Medtech Alert
Tuesday, January 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Paul Davis

Paul Davis

About Paul Davis

Paul has worked in immunology for 45 years and has founded or co-founded eight bioscience businesses since 2002, with Mologic being the most prominent. As Mologic’s chief scientific officer, Paul leads the Centre for Advanced Rapid Diagnostics (CARD), funded by the Bill & Melinda Gates Foundation. Until 2002 he was as a senior scientist at Unilever Research, leading applied immunology, and is one of the inventors of the lateral flow immunoassay.

Related Story

COVID-19

 Mologic and Alamar Biosciences Collaborate to Develop a next Generation COVID-19 Antigen Test | Pharmtech Focus

Mologic and Alamar Biosciences Collaborate to Develop a next Generation COVID-19 Antigen Test

May 5 2022

Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable […]